Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL IMAGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS BY FMRI AND FDG-PET ASSESSMENTS OF MULTIPLE ORAL DOSES OF LTI-291 IN PATIENTS WITH PARKINSON'S DISEASE WITH A GBA1 MUTATION

Trial Profile

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL IMAGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS BY FMRI AND FDG-PET ASSESSMENTS OF MULTIPLE ORAL DOSES OF LTI-291 IN PATIENTS WITH PARKINSON'S DISEASE WITH A GBA1 MUTATION

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs LTI 01 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Lysosomal Therapeutics
  • Most Recent Events

    • 04 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top